Evidence map›Paper›PMID 33677086›Full record

Observational studyTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2021

Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.

S Mahapatra, S Pati

Abstract readObservational Study
In one paragraph

Observational study in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Article
  6. What has changed after the COVID-19 pandemic in the publication process? A look-back to "Transfusion clinique et biologique".Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

S MahapatraC/O- Mr NK Mishra, N-1/256, Nayapalli, IRC Village, 751015 Bhubaneswar, Odisha, India. Electronic address: doctorsmita@rediffmail.com.
S PatiRegional Medical research Centre, Chandrasekharpur, 751023 Bhubaneswar, Odisha, India. Electronic address: drsamghamita12@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID 19 is an acute respiratory disease caused by infection by the virus SARS-COV-2 and has been declared as a pandemic whose specific treatment is still not established. One of the options in the treatment is Convalescent plasma (CP) therapy when there is presence of required amount of neutralizing antibodies in the plasma of recovered COVID patients. Our objective was to analyze the challenges and the constraints encountered in motivation of COVID 19 recovered persons to come for the screening procedures and to convince the selected persons to come for Plasma donation voluntarily. MATERIAL &

methodsThe present retrospective observational study was conducted for a period of five and half months. Out of 1515 number of persons contacted telephonically for Plasma donation, 1291 persons came for screening of whom 1028 persons were eligible for donation, 263 cases were deferred and 966 persons finally donated.

resultsMaximum number of acceptance cases were from males-(98.7%). Of the accepted cases, (41.73%) were from the 18-30 years' age group. 33.94% were from blood group 'O' Rh D positive giving maximum contribution from any blood group. 38.3% of the accepted cases had resolution of all COVID symptoms within time period of 28-40 days. Maximum number of accepted individuals (39.75%) had suffered from multiple symptoms followed by 39.02% of asymptomatic persons. Highest number of Plasma donation was contributed by Odisha Government Police personnel (51.56%). DISCUSSION: In this global ongoing pandemic, the "Fear Factor of contracting the disease" has acted as a major challenge in motivating and convincing a COVID recovered patient for plasma donation. The challenge before the medical professionals was to motivate, educate and convince the potential donors and the society about the likely benefits of convalescent plasma. This could be finally overcome with the help of positive orientation through social and conventional media as well as mass appeal from government side on the benefits of plasma therapy in saving lives in the present pandemic.

Indexed as

AdolescentAdultBlood DonorsCOVID-19COVID-19 SerotherapyFemaleGuidelines as TopicHumansImmunization, PassiveMaleMiddle AgedRetrospective StudiesYoung AdultChallengesConstraintsCOVID 19DeferralMotivationNeutralizing antibodiesPlasma donors

Identifiers

PMID33677086
PMCPMC7931723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.